SCHEMBL30786240

SCHEMBL30786240

C=Cc1ccc(CN2CCCC2)cn1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 6/20 0.52
CHRNB2 P17787 1/20 0.49
CHRNA4 P43681 1/20 0.49
HRH4 Q9H3N8 1/20 0.47
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MBTD1 Q05BQ5 1/20 0.44
L3MBTL3 Q96JM7 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
NCF1 P14598 1/20 0.42
KDR P35968 1/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2929383 0.85 LMNA (0.50) HRH3ALDH1A1KDM4ENCF1
SCHEMBL17646031 0.85 HRH3 (0.53) HRH3ALDH1A1NCF1SMN1; SMN2
SCHEMBL19018657 0.83 HRH3 (0.53) HRH3CHRNB2CHRNA4HRH4ALDH1A1
SCHEMBL30786137 0.81 LTA4H (0.49) HRH3L3MBTL3L3MBTL1CYP2D6
SCHEMBL2930255 0.79 PRKCQ (0.45) HRH3
SCHEMBL31475217 0.77 CXCR4 (0.47) HRH3CHRNB2CHRNA4HRH4ALDH1A1
SCHEMBL4554100 0.75 CHRNB2 (0.56) HRH3CHRNB2CHRNA4HRH4ALDH1A1
SCHEMBL3869875 0.75 HRH3 (0.55) HRH3CHRNB2CHRNA4HRH4ALDH1A1
SCHEMBL1035345 0.75 ALDH1A1 (0.56) HRH3CHRNB2CHRNA4HRH4ALDH1A1
SCHEMBL20476268 0.75 HRH3 (0.55) HRH3CHRNB2CHRNA4HRH4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 HRH3 2004/4885CHRNB2 3285/4885CHRNA4 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.